Technical Analysis for KURA - Kura Oncology, Inc.

Grade Last Price % Change Price Change
C 12.03 -2.51% -0.31
KURA closed down 2.51 percent on Wednesday, March 22, 2023, on 75 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Bollinger Band Squeeze Range Contraction -2.51%
BB Squeeze + Upper Band Touch Range Contraction -2.51%
Inside Day Range Contraction -2.51%
Overbought Stochastic Strength -2.51%
Upper Bollinger Band Touch Strength -2.51%
20 DMA Support Bullish -1.96%
Bollinger Band Squeeze Range Contraction -1.96%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 10 hours ago
Possible NR7 about 10 hours ago
Possible Inside Day about 10 hours ago
Down 2 % about 14 hours ago
Down 1% about 14 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Kura Oncology, Inc. Description

Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule drug candidates that target cell signaling pathways, which drive the progression of various cancers. The company's lead drug candidate, tipifarnib, an inhibitor of protein farnesylation is in Phase II clinical trials used for the treatment of solid tumors, including thyroid, head, neck, urothelial carcinomas, and salivary cancers with HRAS mutations, as well as patients with peripheral T-cell lymphoma. Its product pipeline also comprise preclinical programs, such as orally-available small molecule inhibitors of extracellular-signal-regulated kinases 1 and 2, such as KO-947 and other backup compounds for the treatment of patients with activating mutations in or other dysregulation of the mitogen-activated protein kinase signaling pathway consisting of mutations in KRAS, BRAF, and NRAS; and orally available, small molecule inhibitors of the menin-MLL interaction for the treatment of patients with acute leukemias involving translocations or partial tandem duplications of the mixed lineage leukemia (MLL) gene. The company was founded in 2014 and is headquartered in La Jolla, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Solid Tumors Oncology Lymphoma Leukemia Carcinoma Thyroid Signal Transduction Oncogenes Cell Signaling Protein Kinase Acute Leukemia Blood Cancers Kras Benzamides Ras Subfamily

Is KURA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 19.92
52 Week Low 10.3
Average Volume 646,853
200-Day Moving Average 14.33
50-Day Moving Average 12.57
20-Day Moving Average 11.64
10-Day Moving Average 11.65
Average True Range 0.55
RSI 51.46
ADX 18.17
+DI 21.98
-DI 16.81
Chandelier Exit (Long, 3 ATRs) 10.89
Chandelier Exit (Short, 3 ATRs) 11.96
Upper Bollinger Bands 12.47
Lower Bollinger Band 10.81
Percent B (%b) 0.73
BandWidth 14.28
MACD Line -0.11
MACD Signal Line -0.27
MACD Histogram 0.1588
Fundamentals Value
Market Cap 682.2 Million
Num Shares 56.7 Million
EPS -1.57
Price-to-Earnings (P/E) Ratio -7.67
Price-to-Sales 0.00
Price-to-Book 7.39
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.65
Resistance 3 (R3) 12.72 12.58 12.55
Resistance 2 (R2) 12.58 12.42 12.54 12.51
Resistance 1 (R1) 12.30 12.32 12.23 12.24 12.48
Pivot Point 12.16 12.16 12.13 12.13 12.16
Support 1 (S1) 11.89 12.00 11.82 11.82 11.58
Support 2 (S2) 11.75 11.91 11.71 11.55
Support 3 (S3) 11.47 11.75 11.51
Support 4 (S4) 11.41